BridgeBio Oncology Therapeutics, Inc BBOT
3.95
(0.04)
(1.00%)
as of 25 Sep
- Market cap
- $319.9M
- P/E
- 0.0×
Follow BBOT
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Current Ratio |
— | 8.10 | 12.34 |
Net Debt/EBITDA |
— | 1.93 | 2.93 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.74 | 0.85 |
Capex/Depreciation |
— | (0.24) | (0.99) |
Interest Coverage |
— | 0.00 | 0.00 |
| — | 0.00% | (115.33%) | |
| — | (90.41%) | (43.76%) | |
ROIC |
— | 0.00% | 0.00% |
Return on Tangible Assets |
— | (53.20%) | (33.65%) |
Average Days of Receivables |
— | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (4,269.46) | (3.68) |
Cash per Share |
— | 12,064.42 | 13.66 |
Shareholders Equity per Share |
— | (13,847.83) | 13.20 |
Interest Debt per Share |
— | 0.00 | 0.00 |
Book value per Share |
— | (13,847.83) | 13.20 |
Free Cash Flow |
— | (55.08) | (114.50) |
Working Capital |
— | 139.11 | 397.36 |
Capital Expenditures |
— | (0.05) | (0.61) |
Net Current Asset Value |
— | (184.24) | 395.11 |
| Other line items | |||
Quick Ratio |
— | 7.95 | 12.15 |
Depreciation/Fixed assets |
— | 0.42 | 0.64 |
Cash ROIC |
— | 241.32% | (13.73%) |
Accounts Receivable Turnover |
— | — | 0.00 |
Accounts Payable Turnover |
— | — | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 |
Operating CF per Share |
— | (4,265.66) | (3.66) |
Capex per Share |
— | (3.80) | (0.02) |
Average Receivables |
— | — | 0.23 |
Average Payables |
— | — | 2.22 |
Average Assets |
— | 82.15 | 306.34 |
Average Common Equity |
— | — | 116.23 |
Capex to Sales |
— | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% |
Columns are period end dates